Week of April 18, 2022 | Vol. 11, Issue 16
Events Hosted or Attended by Bourne Partners
May 17-19, 2022 - Philadelphia, PA
May 24-26, 2022 - New York City, NY
April 23-26, 2022 - Palm Beach, FL
June 13-16, 2022 - San Diego, CA
August 27-29, 2022 - Boston, MA
October 2022 - Charlotte, NC
Recent Transactions, Trading Comps, Market Reports, M&A Pipeline
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
A Breakdown of Relevant Trading Multiples
This is a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
Insight Into Healthcare Related Industries
Representative Current Retained Sell-Side And Partnering Opportunities
Project Gateway
Sell-side | Pharma | Generic pharmaceuticals

Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
A Sampling of Industry Headlines From Last Week
As Pfizer plans to lean in on producing its COVID-19 antiviral this year the drugmaker is looking to pick up the developer of a diagnostic smartphone app, which could help get tablets into patients’ hands faster.
Small but mighty transatlantic investment firm Abingworth has caught the attention—and appetite—of the Carlyle Group, who took the opportunity to gain a stronger foothold in life sciences.
Northwell Health and startup studio Aegis Ventures formed a new joint venture last fall that aims to create novel artificial intelligence tools for patient care.
Move over, A: B is taking the lead now, with Be Biopharma closing out a $130 million financing round backed by several industry leaders that will fuel its engineered B cells platform.

TannerMAP works across the broad spectrum of pharma services, creating opportunities that benefit manufacturers and patients alike. Learn more about the division from industry veterans and Tanner EVPs, Rob Keel and John Lagus.

The Tanner team will be attending several networking events in the coming weeks. Let’s connect to discuss how our organizations can improve patient lives, together.